Maternal and Neonatal Complications in Pregnant Women With Polyendocrine Metabolic Ovarian Syndrome: A Nested Prospective Cohort Study.
Adriana C H Neven, Parneet Sethi, William M Hague et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective nested cohort study examined associations between polyendocrine metabolic ovarian syndrome (PMOS) and pregnancy outcomes among 3,645 pregnant women with risk factors for hyperglycemia enrolled in an international, multicenter GDM-treatment trial. PMOS prevalence was 17.1% (95% CI 15.9, 18.3). After adjustment, PMOS was associated with higher odds of early GDM (aOR 1.37 [95% CI 1.10, 1.72]) and a composite of adverse neonatal outcomes (aOR 1.28 [95% CI 1.04, 1.58]). No interactions with baseline BMI or ethnicity were found.
Key findings
- PMOS was associated with higher odds of early GDM (aOR 1.37 [95% CI 1.10, 1.72]).
- The adjusted odds of a composite of adverse neonatal outcomes were higher with PMOS (aOR 1.28 [95% CI 1.04, 1.58]).
- PMOS was associated with neonatal special care or intensive care admission (aOR 1.32 [95% CI 1.05-1.65]).
- PMOS was associated with birth 1.60 days earlier and birth length 0.33 cm shorter; no interactions with BMI or ethnicity were found.
Why it matters
The findings identify PMOS as a marker associated with early GDM and several less favourable neonatal outcomes in a population already at risk for hyperglycemia. Recognising these associations may help inform assessment of pregnancy risk, while the observational design means they do not establish that PMOS causes the outcomes.
What to keep in mind
This was an observational nested cohort, so associations cannot establish causation. Participants were pregnant women with risk factors for hyperglycemia enrolled in a GDM-treatment trial, which may limit applicability to other populations.